The blog of the Presidential Commission for the Study of Bioethical Issues

A Look at How M.D. Anderson Cancer Center Uses Bioethics Educational Materials

The Presidential Commission for the Study of Bioethical Issues (Bioethics Commission) loves hearing from educators who use our pedagogical materials in traditional and nontraditional settings. As a part of its initiative to promote and enhance bioethics education, the Bioethics Commission has produced a library of educational materials to accompany its reports. The Commission aims to contribute to the tools that educators and students can draw upon, with the overall goal of enhancing bioethics education. Happily, many attendees at the recent American Society of Bioethics and Humanities (ASBH) 2014 Annual Meeting reported incorporating these materials into their university lectures.

Colleen M. Gallagher, Ph.D., M.A., L.S.W., F.A.C.H.E., visited our booth at ASBH to tell us that she has used Bioethics Commission educational materials as a part of her curricula. Gallagher, the Chief and Executive Director of the Section of Integrated Ethics in Cancer Care and an Associate Professor, teaches clinical and research interns, fellows and trainees completing certificates in ethics at the University of Texas M.D. Anderson Cancer Center in Houston, TX. She has used modules such as the Study Guide to “Ethically Impossible” STD Research in Guatemala from 1946 to 1948 and Vulnerable Populations in Safeguarding Children: Pediatric Medical Countermeasure Research for courses on research ethics and clinical trials.

“The Study Guide to ‘Ethically Impossible’ helps to guide conversations with our interns on the importance of balancing public health concerns with the needs of the individual,” said Gallagher. She had also used the format from the Study Guide to “Ethically Impossible” to discuss other cases of ethical misconduct in research.

Gallagher said she finds the division of Bioethics Commission educational material into specific topic areas, such as informed consent and vulnerable population, to be especially useful when discussing public health and social policy issues with her classes. “Ethics is very philosophical, and there’s often a lack of consistent methodologies available. The materials created by the Bioethics Commission break down ethics into topic areas with specific case studies and examples,” explained Gallagher. She then had students apply the issues raised in Commission reports and educational modules to population health concerns where they live. Many of her students are professionals who are continuing their educations online. Gallagher, noting the need for a variety of materials and modalities when teaching online courses, said she appreciates the range of resources produced by the Bioethics Commission. She also appreciates the ease with which her students can access the materials for free online.

All Bioethics Commission educational materials are available for free use at bioethics.gov/education. If you have used Commission materials in your lectures, classes, or seminars and would like to provide feedback, please email education@bioethics.gov.

Share this article

Deliberation and Education in Bioethics: Overview

In the final session of its nineteenth public meeting, the Presidential Commission for the Study of Bioethical Issues (Bioethics Commission) heard from a panel of experts on deliberation and bioethics education, a theme that has been central throughout the Commission’s work since it was established by President Obama in 2009.

In introducing the new project this morning, Bioethics Commission Chair Amy Gutmann, Ph.D., noted that while all of the Commission’s reports to date have been topic-specific, its commitment to public bioethics and to related educational and deliberative efforts has been a constant. “Recognizing that education is required for informed deliberation, and deliberation enhances education at all levels, this new report will integrate deliberation and education as overarching themes of the Commission’s work, and focus on their symbiotic relationship as twin pillars of public bioethics,” Gutmann said.

Daniel Levin, Ph.D., associate professor of political science at the University of Utah, started the discussion by addressing the role of deliberation in public bioethics forums—such as the national meetings of the Bioethics Commission—in informing public understanding of bioethics.

Levin noted that public forums such as the Bioethics Commission are important to ensuring that policy discussions on complex and important issues that concern the public—but in which the public isn’t necessarily engaged—are transparent and serve the public.

Research has shown that Americans are “conflict avoidant” and do not like to engage in discussions of controversial issues, Levin said.  However, he added, “Americans are concerned about the process itself, especially that special interests not be allowed to have undue influence, and they believe that the political process should be transparent.”

Next, Diana E. Hess, Ph.D., professor of curriculum and instruction at the University of Wisconsin-Madison and senior vice president of the Spencer Foundation, examined the relationship between democratic deliberation and both public and medical education.

“People need to be taught how to engage in high-quality deliberation,” Hess said, starting in high school and throughout the course of their education, on complex issues, including issues related to bioethics.

She noted that anyone –not just physicians and bioethicists—may at some point in their life be faced with a bioethical decision, such as how to deal with care at the end of life.  “You’ve got a responsibility to prepare people not just to participate in public policy discussions,” Hess told the Commission.  “What is education for? We want to create a better society, but we want people to have better lives.”

Lisa Lehmann, M.D., Ph.D., M.Sc., director of the Center for Bioethics at Brigham and Women’s Hospital and associate professor of medicine and medical ethics at Harvard Medical School, rounded out the panel by focusing on the importance and value of ethics education in the education of medical professionals.

Lehman said bioethics education can foster the “moral courage” needed for medical professionals to “put ethical principle into action.”  She defined moral courage as “the courage to do what’s right for patients, despite the professional risks … even if it conflicts with the law.”

However, she agreed with Hess that all members of society should have some bioethics education, so that they can make informed decisions such as whether to be an organ donor, for example.

Gutmann asked the panel if the example of quarantines during an Ebola outbreak might be the kind of case study that could help with bioethics education.  She noted that such a case study brings science, law, and ethics together.

Hess replied that it is a “close to perfect case study.”  She said that it is both highly authentic and that it has a lot of conflicting core values.

The Bioethics Commission’s next public meeting is scheduled for Feb. 5-6, 2015. The Commission plans to meet in Washington, D.C.

Share this article

Deliberation and Bioethics Education: A Case Study of Public Health Emergency Response

This morning, the Presidential Commission for the Study of Bioethical Issues (Bioethics Commission) turned its attention to its next report topic: deliberation and bioethics education.  The Bioethics Commission advises President Obama and his administration on issues arising from advances in biomedicine and related areas of science and technology and, in so doing, educates the nation on bioethical issues.  This new project will focus on the symbiotic relationship between deliberation and education as twin pillars of public bioethics.  Education is required for informed deliberation, and deliberation enhances education at all levels.

The Bioethics Commission dove into its new project this morning with back-to-back sessions examining a case study in public health emergency response. Guest speakers Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH), andLawrence O. Gostin, J.D., LL.D., university professor and director of Georgetown University’s O’Neill Institute for National & Global Health Law and director of the World Health Organization Collaborating Center on Public Health Law & Human Rights,  brought up compelling ethical topics related to the timely debate of restriction of movement provisions in response to an epidemic.

“There are very few examples that are stronger than a global public health crisis to focus our minds and drive home the importance of public education and proactive deliberation,” explained Bioethics Commission Chair Amy Gutmann, Ph.D.

Gostin launched the discussion by describing the various sets of ethical standards that should come into play as issues like quarantine and restriction of movement are considered.  Quarantine and restriction of movement is just one of the difficult ethical issues that have been brought up by the current Ebola virus disease outbreak in several western African countries.

In particular, Gostin cautioned against blanket quarantines. “When we think carefully, we should use good science and good constitutional law, both of which would require an individualized assessment of risk before limiting individual liberty,” he said.

Gostin also stressed the importance of public trust to effective public health enforcement.  “Whatever decisions policymakers make, they need to be made in partnership and shared understanding with those who are most affected,” Gostin said. “If AIDS taught us anything, it taught us that the first response is social mobilization.”

Next, Fauci discussed how science should inform ethical guidance for public health decision-makers managing Ebola in the United States.  Fauci has played a leading role in the national response to Ebola. He has testified before Congress and has been interviewed by national news media on the importance of a science-based approach to containing the Ebola epidemic in western Africa and minimizing risk in the United States.

Fauci also helped care for a Dallas area nurse who was infected with Ebola while caring for a patient with Ebola.  This involvement, he said, puts him at low risk for infection, and, in some states, would mean that he would be quarantined. He cited a recent public health conference in New Orleans that banned participation of health care workers who had traveled to West Africa – “and those are the very people you want there.”

Blanket quarantines, he said, are not based on scientific evidence, but arise from a desire to assuage public fear.  The real danger, he added, is that blanket quarantines and restrictions can undermine efforts needed to contain outbreaks such as Ebola because they discourage health care workers from providing care to those who are infected.

What’s most needed, Fauci said, is public education.  He contrasted the public response to the early days of the AIDS epidemic with the current reaction to Ebola.  In AIDS, “we had a growing, insidious epidemic and very few people were paying attention to it.  Here we have two cases, and we have mobilized everyone, including the President of the United States.”  He added, “The lesson learned is you’ve got to keep educating the public over and over again.”

Following the case study discussions, the Bioethics Commission went on to broaden its discussion to the goals and contributions of deliberation and bioethics education generally.

Share this article

Live from Salt Lake City

Welcome back to live blog coverage of the nineteenth public meeting of the Presidential Commission for the Study of Bioethical Issues (Bioethics Commission).  The Bioethics Commission is meeting in Salt Lake City today, November 6, 2014, from 9 a.m. to noon MT.

Yesterday, the Bioethics Commission continued its review of ethical issues associated with neuroscience research and application and began deliberating on recommendations in response to President Obama’s request regarding the BRAIN Initiative.  Today the Bioethics Commission will begin discussing its new project – deliberation and bioethics education.

The Bioethics Commission will hear from two panels this morning.  For the first panel, guest speakers Anthony S. Fauci, M.D., of the National lnstitutes of Health and Lawrence O. Gostin of the World Health Organization Collaborating Center on Public Health Law and Human Rights will present on a case study of public health emergency response.  The second panel will provide an overview of deliberation and bioethics education, with remarks by Daniel Levin, Ph.D., associate professor of political science at the University of Utah; Diane E. Hess, Ph.D., professor of curriculum and instruction at the University of Wisconsin-Madison; and Lisa Lehmann, M.D., Ph.D., M.Sc., director of the Center for Bioethics at Brigham and Women’s Hospital.

You can follow the proceedings of the Bioethics Commission’s meeting here at this blog, and on the live webcast of the Bioethics Commission’s website.  The webcast and meeting transcripts will be archived and available following the meeting at www.bioethics.gov.

Share this article

Bioethics Commission Discusses Law and Neuroscience

This afternoon, the Presidential Commission for the Study of Bioethical Issues (Bioethics Commission) turned its attention to law and neuroscience as part of its deliberations on potential recommendations related to neuroscience that it may offer to the President.

Bioethics Commission Chair Amy Gutmann, Ph.D., began by focusing discussion questions around whether and how to use neuroscience technologies in the courtroom.

“What can neuroscience in its current capacity tell us about whether any individual is legally blameworthy for his or her actions?” Gutmann asked. “What is the potential for neuroscience to answer this question? What can it tell us about moral responsibility and blameworthiness, as distinct from legal responsibility and blameworthiness?”

Commission Member Nita A. Farahany, J.D., Ph.D., framed the discussion by noting the different legal contexts in which neuroscience research is being cited. For example, lawyers are bringing neuroscience research into the courtroom to substantiate claims about defendants’ competency to stand trial, as well as to challenge traditional notions about what a mental state is and how it should be measured. Neuroscience has also come up in sentencing as a way of determining the degree to which a person is morally responsible because of diminished capacity, and whether sentencing for such an individual should be weighted more toward retribution or toward rehabilitation. Finally, criminal courts have also looked to neuroscience as a predictor of a defendant’s future dangerousness.

Farahany said she has also seen neuroscience research cited in in certain civil cases. In the past, it has been difficult to prove whether a person is suffering pain from exposure to a toxic substance. Now, some civil plaintiffs are using neuroscience to do just that. In the arena of constitutional law, the U.S. Supreme Court has cited neuroscience research with regard to the culpability of juvenile defendants accused of capital crimes. Farahany noted that neuroscience is also beginning to highlight gaps in certain constitutional protections, such as freedom of speech and new technologies that reveal the brain’s visual imagery.

Farahany cautioned about overstating the capacity of neuroscience to inform law. “When we start using a science like neuroscience to predict behavior before it can do so, it can derail the credibility of science as a whole,” she said, citing “a duty to tread carefully in an area of nascent science.”

Commission Member John D. Arras, Ph.D., observed that some legal experts have questioned whether neuroscience upends the legal notion of people as ‘agents of action’ capable of making decisions in accordance with society’s rules and laws. This argument, he said, “strips people of their personhood and views them as things to be moved around and not responsible for their actions. That is something to worry about.”

Tomorrow the Bioethics Commission will shift its focus from neuroscience and related ethical issues to deliberation and bioethics education. The discussion will include a panel examining a case study of public health emergency response featuring Anthony S. Fauci, M.D., of the National lnstitutes of Health and Lawrence O. Gostin of the World Health Organization Collaborating Center on Public Health Law and Human Rights.

Share this article

Bioethics Commission Deliberates Consent Capacity

The Presidential Commission for the Study of Bioethical Issues (Bioethics Commission) is devoting the majority of today’s public meeting in Salt Lake City to discussing potential neuroscience-related recommendations that it could offer to President Obama.

This morning, Bioethics Commission Chair Amy Gutmann, Ph.D., noted that three areas have emerged throughout the public meetings at which the Bioethics Commission has discussed ethical issues related to neuroscience. They are cognitive enhancement, consent capacity, and law and neuroscience. A list of Commission meetings relevant to neuroscience can be found here on bioethics.gov.

After spending the second half its morning discussing cognitive enhancement, the Bioethics Commission moved on to discuss consent capacity, specifically research with participants whose capacity is potentially diminished or absent. Many of the conditions that neuroscientists study can affect a person’s capacity to consent to research.

“To generate knowledge about and treatments for these conditions, affected individuals must be included in research – critically, with ethical safeguards in place,” said James W. Wagner, Ph.D., Bioethics Commission Vice Chair. “Several ethical considerations arise. For example, how do we ensure adequate protections for research participants with impaired capacity? What procedures should be in place to assess consent capacity? And how might we address stigma associated with impaired consent capacity?” Wagner asked.

Wagner asked Commission Members Daniel P. Sulmasy, M.D., Ph.D., FACP, and Christine Grady, R.N., Ph.D, to help frame the discussion.

Sulmasy suggested that the Bioethics Commission consider diminished capacity not only in the research setting but in the clinical setting as well. He noted that research on clinical capacity is largely based on clinical exams of patients. Instead of viewing capacity solely as an issue in neuroscience research, it could be treated as a topic of neuroscience research. Such research, he said, could “help us better understand what capacity is from a scientific point of view, how to assess it, and how to assess it again along a very complicated continuum…and, if there are ways, how to improve or restore capacity.”

Grady addressed some of the legal issues around capacity. She observed that capacity is not a static condition; it changes. Therefore researchers need to keep in mind that even after a person with diminished capacity gives consent, there needs to be ongoing capacity assessment as additional decision points arise.

She also noted that, in practice, laws regarding capacity and decision-making are made at the state level, so there is little uniformity. Furthermore, very few state laws explicitly address capacity to make decisions regarding research participation; most are geared toward medical decisions.

Grady also noted that surrogates are frequently viewed as a solution for decision-making issues, but that there is a need for greater clarity around the appointment of legally authorized surrogates to act on behalf of persons with diminished capacity. “Who should be able to serve as a legally authorized representative for the purposes of enrolling people in research?” she said.

The Bioethics Commission will spend its last session today discussing law and neuroscience.

Share this article

Bioethics Commission Deliberates Neuroscience-Related Recommendations

Following this morning’s presentations and discussion about the ethical responsibilities of direct-to-consumer neuroscience companies, the Presidential Commission for the Study of Bioethical Issues (Bioethics Commission) launched into the next phase of its neuroscience project – deliberating its recommendations for the President. As part of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, President Obama asked the Bioethics Commission to “identify proactively a set of core ethical standards – both to guide neuroscience research and to address some of the ethical dilemmas that may be raised by the application of neuroscience research findings.”
The Commission provided its initial recommendations earlier this year in volume one of its Gray Matters report, in which it stressed the importance of ethics integration early and throughout neuroscience research. Today’s deliberations will inform the Commission’s recommendations for Gray Matters, volume 2. Bioethics Commission Chair, Amy Gutmann, Ph.D., said the rest of the day’s discussion would center on three topics: cognitive enhancement, consent capacity in neuroscience research, and law and neuroscience.

The Bioethics Commission addressed the topic of cognitive enhancement in depth during its August 2014 meeting in Washington, D.C. During this morning’s discussion, Gutmann noted that cognitive enhancement can include the on-label, off-label, and direct-to-consumer use of neuroscience drugs and technologies. She turned to Commission Member Stephen L. Hauser, M.D. to kick off the session.

“There is nothing inherently wrong with the concept of cognitive enhancement,” Hauser said. “But … are there limits and, if so, what are they?

He identified three types of products that fall under the category of cognitive enhancement: pharmaceuticals, including stimulants such as Adderall and Ritalin, off-label use of drugs that work on multiple neural transmitter systems, and other drugs that work to enhance memory; electrical adjuncts that stimulate or modulate the brain; and learning tools enhanced by neuroscience such as video games.

Hauser also suggested that the Commission consider broadening the concept of cognitive enhancement “to think about the range of ways that the human nervous system may be enhanced. This involves, importantly, motor behavior as well as cognitive enhancements.” In addition, he emphasized the importance of “promoting an informed public” through education, communications, and fact-checking mechanisms.
Next, Commission Member Anita L. Allen, J.D., Ph.D., outlined other areas that the Commission might explore, including additional research on the prevalence of cognitive enhancement tools and products and with what populations; the importance of self-help and self-care for people who want to enhance their cognition; ensuring equitable access to cognitive enhancement products and programs; as well as questions around coercion.

“We need to be recommending that ethicists spend a great deal of time as we move forward assessing whether or not we want to go far ahead in the area of enhancements. Do we want to get to normal or do we want to get to superhuman?” Allen said. “If science makes that possible, should we go that way? … What’s wrong with that? Is anything wrong with wanting to be better than we are?”
When the Commission reconvenes later this afternoon, it will turn the focus of its deliberations to consent capacity for neuroscience research.

Share this article

Ethical Responsibilities of Direct-to-Consumer Neuroscience Companies

As part of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, President Obama asked the Presidential Commission for the Study of Bioethical Issues (Bioethics Commission) to “identify proactively a set of core ethical standards – both to guide neuroscience research and to address some of the ethical dilemmas that may be raised by the application of neuroscience research findings.”

This morning, the Bioethics Commission resumed its consideration of ethical issues related to direct-to-consumer (DTC) neuroscience, including products like dietary supplements, neurofeedback devices, and even memory games.  At its last meeting, the Bioethics Commission heard from experts representing the U.S. Food and Drug Administration and the neurotechnology sector.  Today, another regulatory expert from the U.S. Federal Trade Commission (FTC) kicked off the discussion.

Serena  Viswanathan, J.D., assistant director of the Division of Advertising Practices in the FTC’s Bureau of Consumer Protection, addressed what companies that produce, advertise, and market DTC neuroscience products must do to meet the FTC’s regulatory requirements.

“The basic principles of FTC advertising law are that advertising must be truthful and not be misleading and that advertisers of products must have a meaningful basis for their advertising claims,” said Viswanathan.  “Neuroscience is a complicated area but the basic evaluation we would do is similar to any other health case.”

Margaret Eaton, Pharm, D., J.D., former research scholar at the Stanford University Center for Biomedical Ethics and former lecturer at the Stanford University Graduate School of Business and School of Medicine, gave a presentation entitled “Ethical Responsibilities of DTC Neuroscience Companies.”  Eaton focused on the potential ethical responsibilities of DTC neuroscience companies to customers around concerns such as validity and safety requirements, protection of consumer privacy, and transparency of conflicts of interest.

As an example of problematic advertisements for neuroscience-based products, Eaton described how some manufacturers of psychotropic drugs have sought to create a perceived need for their products by encouraging consumers to take self-assessment tests developed by or for the company.  Eaton said she took one such test, which included 20 questions such as did she ever feel “down-hearted, blue, or sad.”  The available answers were “not often,” “sometimes,” “often” or “all the time.”  To every question, she answered “sometimes.”

“Most people sometimes have felt these symptoms; in other words, I think it’s normal,” Eaton said.  “However, my answers resulted in a recommendation to see my doctor for an evaluation of depression.”

Eaton also acknowledged that when it comes to the issue of conflict of interest, the main focus has been financial gain.  However, she agreed that in academia the conflicts could be stronger when it comes to what she called “reputational perks.”  Such perks, she said, “lead to promotion, recognition, grants, and they are intricately linked.  We do a disservice when we exclude these from conflicts of interest.”

The Bioethics Commission will use this discussion to transition into sessions it has scheduled for the rest of the day during which it will deliberate and formulate its recommendations related to neuroscience research for the President.

Share this article

Live from Salt Lake City

Welcome to the live blog of the nineteenth public meeting of the Presidential Commission for the Study of Bioethical Issues (Bioethics Commission). The Bioethics Commission is meeting in Salt Lake City today, November 5, from 9 a.m. to 4:30 p.m. MT, and tomorrow, November 6, from 9 a.m. to noon MT.

During this meeting, the Bioethics Commission will continue its review of the ethical issues associated with neuroscience research and the application of neuroscience research findings, as requested by President Obama. This morning, the Bioethics Commission will hear from two speakers who will address the ethical responsibilities of companies that market neuroscience products directly to consumers: Serena Viswanathan, J.D., of the U.S. Federal Trade Commission; and Margaret Eaton, Pharm.D., J.D., of Stanford University.

The Bioethics Commission will spend the remainder of the day deliberating its recommendations to the President.

You can follow the proceedings of the Bioethics Commission’s meeting here at this blog, and on the live webcast. The webcast and transcripts from the meeting will be archived and available following the meeting at www.bioethics.gov.

Share this article

Bioethics Commission FAQs from ASBH

Last week the Presidential Commission for the Study of Bioethical Issues (Bioethics Commission) attended the American Society for Bioethics and Humanities (ASBH) annual meeting, held in San Diego, California October 16-19. Along with leading multiple presentations, the Bioethics Commission was pleased to host a booth in the conference’s exhibition hall. The exhibit featured Commission reports as well as new communications materials. Several hundred copies of “Ethically Impossible” STD Research in Guatemala from 1946 to 1948, Safeguarding Children: Pediatric Medical Countermeasure Research, Anticipate and Communicate: Ethical Management of Incidental and Secondary Findings, and Gray Matters: Integrative Approaches for Neuroscience, Ethics, and Society flew off the table so quickly that we ran out of copies before the end of the conference’s second day. If you were not able to get a hard copy of your favorite report, all materials are available for free download on our website.

ASBH 2014 Booth

ASBH provided an opportunity to interact with many colleagues from across the bioethics community; many attendees reported using our educational resources in their classrooms. The Bioethics Commission welcomes feedback and likes to hear how its materials are being used, so if you have used our materials and are interested in sharing your experience, please email education@bioethics.gov!

The Bioethics Commission received many great questions at our exhibit. Here are some of the most commonly asked questions:

What is the Bioethics Commission currently working on?
The Commission is continuing its work on neuroscience. At its next public meeting on Nov. 5-6 in Salt Lake City, Utah, the Commission will be deliberating recommendations on neuroscience and related ethical issues. Gray Matters, Vol. 2, thefollow up to the May 2014 report Gray Matters: Integrative Approaches for Neuroscience, Ethics, and Society, is expected to be released in spring 2015 and will address important ethical issues related to applications and implications of neuroscience research.

In addition to neuroscience research and related ethical issues, the Bioethics Commission will begin discussions on its next topic – a self-directed topic – the role of deliberation and education in bioethics– at the November meeting. The Commission will focus on their symbiotic relationship as twin pillars of public bioethics: Education is required for informed deliberation, and deliberation enhances education at all levels.

How does the Bioethics Commission choose the topics that it works on?
The Executive Office of the President may ask the Bioethics Commission to study a particular topic or answer a particular question and report back; Gray Matters and “Ethically Impossible” are examples of two reports that came at the request of the President. In addition, the Commission may accept suggestions of issues for consideration from executive departments and agencies and the public, as it deems appropriate in support of its mission.

How does the Bioethics Commission promote public bioethics?
All Commission deliberations occur in public during its quarterly meetings. Anyone who is interested may attend these public meetings, or watch the meeting via live webcast. These meetings allow for the unique opportunity to witness the live deliberations of a national bioethics commission—public bioethics in action. The Commission welcomes input from anyone wishing to provide public comment on any issue before it, and is particularly interested in receiving comments and questions during meetings that are responsive to specific sessions. Written comments are accepted in advance of each meeting; please address written comments by email to info@bioethics.gov. In addition, the Commission posts regular updates to its blog—blog.bioethics.gov—and to Twitter.

How do you get to be on the Bioethics Commission?
Each Commission member is selected by the Executive Office of the President and serves for the term of the Commission.

Are there any staff employment opportunities available?
Currently there are no openings for staff positions. When opportunities come up, we post all of our vacancies on our website under Employment Opportunities.

How do I get in touch with the Bioethics Commission?
The best way to contact the Commission is via email. All correspondence is reviewed and logged. For public comments and questions please email info@bioethics.gov; for comments on or questions about educational materials please email education@bioethics.gov.

What happens to the commission after President Obama’s term is over?
Like all federal advisory bodies, the Bioethics Commission must be renewed every two years. The Executive Order under which the Commission currently operates expires in September 2015. Even if President Obama again extends his order and issues an additional continuance for the Commission, it is expected that this Commission, in its current form, will complete its work at the close of President Obama’s term in January 2017. At that time, it is also expected – though not guaranteed – that the next president will establish his or her own bioethics commission.

Where can I access reports published by previous bioethics commissions?
The Presidential Commission for the Study of Bioethical Issues is a separate commission from those established by previous presidents, and therefore does not maintain archives for previous commissions. Our website provides links to various archived material from past commissions, including some links to previous commissions’ reports. Most of these archives are maintained by either Georgetown University or George Washington University.

Thanks to all who stopped by our booth this year!

 

 

Share this article

About blog.Bioethics.gov

This is a space for the members and staff of the Presidential Commission for the Study of Bioethical Issues to communicate with the public about the work of the commission and to discuss important issues in bioethics.

Learn more about the Presidential Commission for the Study of Bioethical Issues.

Subscribe

You can receive updates about our blog via email subscription, RSS feed, or follow the Bioethics Commission on Twitter.